fda warning letters compounded semaglutide november 2025 warns telehealth companies over GLP-1s FDA Sends Warning Letters to

Reason #5: Hormones or Metabolism May Be Slowing You Down Sometimes, slow progress is tied to something deeper

Additional Resources Mercer: GLP-1 Considerations for 2026 Peterson-KFF: Employer Perspectives on GLP-1 Coverage Costs Blue Cross Blue Shield: How GLP-1s Could Increase Employer Premiums Morgan Lewis: GLP-1 Coverage, Obesity, and the ADA Related: ERISA Voluntary Benefits Compliance Checklist for Brokers (BenefitFlow) Sources for statistics cited in this article include SHRM, EBRI, HUB International, KFF, Mercer, Blue Cross Blue Shield Association, and the Business Group on Health

No supplier of IGF-1 LR3 is FDA-approved for human use

The oral GLP-1 pill may be appropriate for adults with obesity or overweight who also have related health conditions such as type 2 diabetes or high blood pressure